A detailed history of Prudential Financial Inc transactions in Regenxbio Inc. stock. As of the latest transaction made, Prudential Financial Inc holds 50,024 shares of RGNX stock, worth $531,755. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,024
Previous 47,144 6.11%
Holding current value
$531,755
Previous $846,000 24.59%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$12.17 - $24.61 $35,049 - $70,876
2,880 Added 6.11%
50,024 $1.05 Million
Q4 2023

Feb 13, 2024

SELL
$12.89 - $20.82 $3,557 - $5,746
-276 Reduced 0.58%
47,144 $846,000
Q3 2023

Nov 13, 2023

SELL
$16.46 - $19.99 $349,775 - $424,787
-21,250 Reduced 30.95%
47,420 $780,000
Q2 2023

Aug 11, 2023

SELL
$17.23 - $21.71 $47,244 - $59,528
-2,742 Reduced 3.84%
68,670 $1.37 Million
Q1 2023

May 12, 2023

BUY
$18.08 - $24.55 $14,463 - $19,640
800 Added 1.13%
71,412 $1.35 Million
Q4 2022

Feb 14, 2023

BUY
$20.4 - $24.73 $419,117 - $508,077
20,545 Added 41.04%
70,612 $0
Q3 2022

Nov 04, 2022

SELL
$22.29 - $35.04 $897,952 - $1.41 Million
-40,285 Reduced 44.59%
50,067 $1.32 Million
Q2 2022

Aug 15, 2022

BUY
$19.35 - $35.04 $984,624 - $1.78 Million
50,885 Added 128.93%
90,352 $2.23 Million
Q1 2022

May 13, 2022

SELL
$24.62 - $34.31 $74,204 - $103,410
-3,014 Reduced 7.09%
39,467 $1.31 Million
Q4 2021

Feb 14, 2022

BUY
$30.19 - $40.28 $22,431 - $29,928
743 Added 1.78%
42,481 $1.39 Million
Q3 2021

Nov 15, 2021

BUY
$29.09 - $45.68 $79,677 - $125,117
2,739 Added 7.02%
41,738 $1.75 Million
Q2 2021

Aug 16, 2021

SELL
$32.46 - $40.48 $36,712 - $45,782
-1,131 Reduced 2.82%
38,999 $1.52 Million
Q1 2021

May 12, 2021

BUY
$33.61 - $49.95 $191,913 - $285,214
5,710 Added 16.59%
40,130 $1.37 Million
Q4 2020

Feb 16, 2021

SELL
$26.52 - $49.35 $16,972 - $31,584
-640 Reduced 1.83%
34,420 $1.56 Million
Q3 2020

Nov 16, 2020

SELL
$27.01 - $40.26 $72,386 - $107,896
-2,680 Reduced 7.1%
35,060 $965,000
Q2 2020

Aug 12, 2020

SELL
$27.75 - $43.44 $317,460 - $496,953
-11,440 Reduced 23.26%
37,740 $1.39 Million
Q1 2020

May 12, 2020

SELL
$21.5 - $54.2 $40,076 - $101,028
-1,864 Reduced 3.65%
49,180 $1.59 Million
Q4 2019

Feb 11, 2020

SELL
$34.54 - $44.87 $208,483 - $270,835
-6,036 Reduced 10.57%
51,044 $2.09 Million
Q3 2019

Nov 13, 2019

SELL
$31.84 - $50.88 $1.82 Million - $2.9 Million
-57,060 Reduced 49.99%
57,080 $2.03 Million
Q2 2019

Aug 08, 2019

BUY
$42.0 - $59.29 $302,400 - $426,888
7,200 Added 6.73%
114,140 $0
Q1 2019

May 15, 2019

SELL
$40.82 - $62.45 $1.79 Million - $2.74 Million
-43,830 Reduced 29.07%
106,940 $0
Q4 2018

Feb 07, 2019

BUY
$39.11 - $75.15 $27,377 - $52,605
700 Added 0.47%
150,770 $6.32 Million
Q3 2018

Nov 07, 2018

BUY
$65.0 - $82.15 $280,150 - $354,066
4,310 Added 2.96%
150,070 $0
Q2 2018

Aug 13, 2018

BUY
$27.2 - $74.35 $3.04 Million - $8.32 Million
111,850 Added 329.84%
145,760 $0
Q1 2018

May 04, 2018

BUY
$24.05 - $37.5 $253,968 - $396,000
10,560 Added 45.22%
33,910 $0
Q4 2017

Feb 13, 2018

BUY
$26.0 - $34.6 $607,100 - $807,910
23,350
23,350 $776,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $460M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.